Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Day One Biopharma to acquire Mersana Therapeutics for up to $285M to boost its cancer drug pipeline.
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics in a deal worth up to $285 million, including an upfront $25 per share cash payment and potential milestone-based payments of up to $30.25 per share.
The acquisition, pending regulatory and shareholder approval, aims to expand Day One’s oncology pipeline, particularly in pediatric cancers, and integrate Mersana’s antibody-drug conjugate platform and clinical-stage candidates.
Mersana’s lead drug, Emi-Le, is a key focus.
Day One reported strong third-quarter sales of its lead drug, tovorafenib, with revenue rising to $38.5 million and prescriptions increasing 18% quarter-over-quarter.
The company raised its 2025 revenue forecast for tovorafenib to $145–$150 million and ended the quarter with $451.6 million in cash.
The tender offer is expected to begin within 10 business days of November 12, 2025.
Day One Biopharma adquiere Mersana Therapeutics por hasta $285 millones para impulsar su línea de medicamentos contra el cáncer.